Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

AIMS: To compare 12‐month clinical effectiveness of insulin glargine 300 units/mL (Gla‐300) versus first‐generation basal insulin analogues (BIAs) (insulin glargine 100 units/mL [Gla‐100] or insulin detemir [IDet]) in patients with type 2 diabetes (T2D) who were at high risk of hypoglycaemia and swi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Sean D., Freemantle, Nick, Gupta, Rishab A., Wu, Jasmanda, Nicholls, Charlie J., Westerbacka, Jukka, Bailey, Timothy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754248/
https://www.ncbi.nlm.nih.gov/pubmed/34807513
http://dx.doi.org/10.1002/edm2.306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754248/
https://www.ncbi.nlm.nih.gov/pubmed/34807513
http://dx.doi.org/10.1002/edm2.306

Ejemplares similares